Page Content
#ffffff
Anonymous user
On
Authenticated user
On
Premium
On
Paid / Sponsored
On
Featured
On
Featured Thumbnail
Image
Source
1. https://clinicaltrials.gov/study/NCT04718103. 2. https://clinicaltrials.gov/study/NCT04719832. 3. Jackson DJ, Wechsler ME, Jackson DJ, et al. Twice-Yearly Depemokimab in Severe Asthma with an Eosinophilic Phenotype. N Engl J Med. 2024;391(24):2337
Speciality
Currency
Sub Speciality
Sub Sub Speciality
Short Description
Depemokimab is an ultra-long-acting biologic therapy with enhanced binding affinity for interleukin-5 that may enable effective 6-month dosing intervals.
User Segments
Featured Order
0